TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer

British Journal of Cancer

Volumn 99, Issue 11, 2008, Pages 1849-1858

  Knight, J F ^a   Shepherd, C J ^a   Rizzo, S ^a   Brewer, D ^a   Jhavar, S ^a   Dodson, A R ^b   Cooper, C S ^a   Eeles, R ^a   Falconer, A ^a,c   Kovacs, G ^d   Garrett, M D ^a   Norman, A R ^e   Shipley, J ^a   Hudson, D L ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c CHARING CROSS HOSPITAL   (United Kingdom)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

c Cbl; Differentiation; Laser capture microdissection; Prostate cancer; TEAD1

Indexed keywords

CBL PROTEIN; ONCOPROTEIN; PROTEIN TEAD 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BASAL CELL; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; DISEASE MARKER; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; DNA-BINDING PROTEINS; EPITHELIAL CELLS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MICRODISSECTION; MIDDLE AGED; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-CBL; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 56749105608     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604774     Document Type: Article

References (56)

1. Alam TN, O'Hare MJ, Laczko I, Freeman A, Al-Beidh F, Masters JR, Hudson DL (2004) Differential expression of CD44 during human prostate epithelial cell differentiation. J Histochem Cytochem 52: 1083-1090
2. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Bono JS, Scardino P, Cuzick J, Cooper CS (2008) Duplication of the fusion of TMPRSS2 to ERG secquences identifies fatal human prostate cancer. Oncogene 27: 253-263
3. Bandura JL, Edgar BA (2008) Yorkie and Scalloped: partners in growth activation. Dev Cell 14: 315-316
4. Bello-DeOcampo D, Kleinman HK, Deocampo ND, Webber MM (2001) Laminin-1 and alpha6beta1 integrin regulate acinar morphogenesis of normal and malignant human prostate epithelial cells. Prostate 46: 142-153
5. Bonkhoff H, Remberger K (1996) Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 28: 98-106
6. Browne TJ, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA (2004) Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Hum Pathol 35: 1462-1468
7. Bui M, Reiter RE (1998) Stem cell genes in androgen-independent prostate cancer. Cancer Metastasis Rev 17: 391-399
8. Chiang YC, Teng SC, Su YN, Hsieh FJ, Wu KJ (2003) c-Myc directly regulates the transcription of the NBS1 gene involved in DNA double-strand break repair. J Biol Chem 278: 19286-19291
9. Cifuentes E, Mataraza JM, Yoshida BA, Menon M, Sacks DB, Barrack ER, Reddy GP (2004) Physical and functional interaction of androgen receptor with calmodulin in prostate cancer cells. Proc Natl Acad Sci USA 101: 464-469
10. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951
11. Daly-Burns B, Alam TN, Mackay A, Clark J, Shepherd CJ, Rizzo S, Tatoud R, O'Hare MJ, Masters JR, Hudson DL (2007) A conditionally immortalized cell line model for the study of human prostatic epithelial cell differentiation. Differentiation 75: 35-48
12. de Melker AA, van der Horst G, Calafat J, Jansen H, Borst J (2001) c-Cbl ubiquitinates the EGF receptor at the plasma membrane and remains receptor associated throughout the endocytic route. J Cell Sci 114: 2167-2178
13. Debnath J, Muthuswamy SK, Brugge JS (2003) Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30: 256-268
14. Edick MJ, Tesfay L, Lamb LE, Knudsen BS, Miranti CK (2007) Inhibition of integrin-mediated crosstalk with epidermal growth factor receptor/Erk or Src signaling pathways in autophagic prostate epithelial cells induces caspase-independent death. Mol Biol Cell 18: 2481-2490
15. Enomoto H, Ozaki T, Takahashi E, Nomura N, Tabata S, Takahashi H, Ohnuma N, Tanabe M, Iwai J, Yoshida H, Matsunaga T, Sakiyama S (1994) Identification of human DAN gene, mapping to the putative neuroblastoma tumor suppressor locus. Oncogene 9: 2785-2791
16. Espina V, Heiby M, Pierobon M, Liotta LA (2007) Laser capture microdissection technology. Expert Rev Mol Diagn 7: 647-657
17. Fend F, Emmert-Buck MR, Chuaqui R, Cole K, Lee J, Liotta LA, Raffeld M (1999) Immuno-LCM: laser capture microdissection of immunostained frozen sections for mRNA analysis. Am J Pathol 154: 61-66
18. Fernandez PL, Arce Y, Farre X, Martinez A, Nadal A, Rey MJ, Peiro N, Campo E, Cardesa A (1999) Expression of p27/Kip1 is downregulated in human prostate carcinoma progression. J Pathol 187: 563-566
19. Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A, Southgate C, Dowe A, Dearnaley D, Jhavar S, Eeles R, Feber A, Cooper CS (2004) Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 23: 5871-5879
20. Fournier TM, Lamorte L, Maroun CR, Lupher M, Band H, Langdon W, Park M (2000) Cbl-transforming variants trigger a cascade of molecular alterations that lead to epithelial mesenchymal conversion. Mol Biol Cell 11: 3397-3410
21. Gamble SC, Chotai D, Odontiadis M, Dart DA, Brooke GN, Powell SM, Reebye V, Varela-Carver A, Kawano Y, Waxman J, Bevan CL (2007) Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene 26: 1757-1768
22. Givalos N, Gakiopoulou H, Skliri M, Bousboukea K, Konstantinidou AE, Korkolopoulou P, Lelouda M, Kouraklis G, Patsouris E, Karatzas G (2007) Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer. Mod Pathol 20: 159-166
23. Gupta M, Kogut P, Davis FJ, Belaguli NS, Schwartz RJ, Gupta MP (2001) Physical interaction between the MADS box of serum response factor and the TEA/ATTS DNA-binding domain of transcription enhancer factor-1. J Biol Chem 276: 10413-10422
24. Gupta MP, Amin CS, Gupta M, Hay N, Zak R (1997) Transcription enhancer factor 1 interacts with a basic helix-loop-helix zipper protein, Max, for positive regulation of cardiac alpha-myosin heavy-chain gene expression. Mol Cell Biol 17: 3924-3936
25. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816
26. Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L, Angel P, Mayer D (2005) Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res 11: 5146-5152
27. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, Schalken JA (2003) DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 46: 271-272
28. Hudson DL, Guy AT, Fry P, O'Hare MJ, Watt FM, Masters JR (2001) Epithelial cell differentiation pathways in the human prostate: identification of intermediate phenotypes by keratin expression. J Histochem Cytochem 49: 271-278
29. Ibrahim GK, Kerns BJ, MacDonald JA, Ibrahim SN, Kinney RB, Humphrey PA, Robertson CN (1993) Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues. J Urol 149: 170-173
30. Kawano Y, Kitaoka M, Hamada Y, Walker MM, Waxman J, Kypta RM (2006) Regulation of prostate cell growth and morphogenesis by Dickkopf-3. Oncogene 25: 6528-6537
31. Klokk TI, Kilander A, Xi Z, Waehre H, Risberg B, Danielsen HE, Saatcioglu F (2007) Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. Cancer Res 67: 5221-5230
32. Knudsen BS, Edlund M (2004) Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res 91: 31-67
33. Li A, Varney M, Singh R (2004) Constitutive expression of growth regulated oncogene (gro) in human colon carcinoma cells with different metastatic potential and its role in regulating their metastatic phenotype. Clin Exp Metastasis 21: 571-579
34. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Marzo AM (2002) α-Methylacyl-CoA Racemase. A new molecular marker for prostate cancer. Cancer Res 62: 2220-2226
35. Maeda T, Chapman DL, Stewart AF (2002) Mammalian vestigial-like 2, a cofactor of TEF-1 and MEF2 transcription factors that promotes skeletal muscle differentiation. J Biol Chem 277: 48889-48898
36. McCabe NP, De S, Vasanji A, Brainard J, Byzova TV (2007) Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene 26: 6238-6243
37. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML (1992) Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944
38. Pascal LE, True LD, Campbell DS, Deutsch EW, Risk M, Coleman IM, Eichner LJ, Nelson PS, Liu AY (2008) Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genomics 9: 246
39. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG (2007) Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res 67: 6796-6805
40. Peschard P, Fournier TM, Lamorte L, Naujokas MA, Band H, Langdon WY, Park M (2001) Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell 8: 995-1004
41. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LW (1995) c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 154: 293-298
42. Sadoul K, Lang J, Montecucco C, Weller U, Regazzi R, Catsicas S, Wollheim CB, Halban PA (1995) SNAP-25 is expressed in islets of Langerhans and is involved in insulin release. J Cell Biol 128: 1019-1028
43. Sawada A, Kiyonari H, Ukita K, Nishioka N, Imuta Y, Sasaki H (2008) Redundant roles of Tead1 and Tead2 in notochord development and the regulation of cell proliferation and survival. Mol Cell Biol 28: 3177-3189
44. Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, Walz J, Chun FH, Haese A, Kollermann J, Graefen M, Huland H, Sauter G, Simon R, Erbersdobler A (2007) Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 13: 6579-6584
45. Shepherd CJ, Rizzo S, Ledaki I, Davies M, Brewer D, Attard G, de Bono J, Hudson DL (2008) Expression profiling of CD133(+) and CD133(-) epithelial cells from human prostate. Prostate 68: 1007-1024
46. Signoretti S, Pires MM, Lindauer M, Horner JW, Grisanzio C, Dhar S, Majumder P, McKeon F, Kantoff PW, Sellers WR, Loda M (2005) p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci USA 102: 11355-11360
47. Swaminathan G, Tsygankov AY (2006) The Cbl family proteins: ring leaders in regulation of cell signaling. J Cell Physiol 209: 21-43
48. Takahashi H, Kobayashi H, Matsuo S, Iizuka H (1995) Repression of involucrin gene expression by transcriptional enhancer factor 1 (TEF-1). Arch Dermatol Res 287: 740-746
49. Thien CB, Langdon WY (2001) Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2: 294-307
50. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Verambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648
51. van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, Witjes JA, Jansesn CF, Mulders PF, Rittenhouse HG, Schalken JA (2008) Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 68: 1215-1222
52. Wang H, McKnight NC, Zhang T, Lu ML, Balk SP, Yuan X (2007) SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Cancer Res 67: 528-536
53. Webber MM, Bello D, Kleinman HK, Hoffman MP (1997) Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis 18: 1225-1231
54. Wu S, Liu Y, Zheng Y, Dong J, Pan D (2008) The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. Dev Cell 14: 388-398
55. Zhang L, Ren F, Zhang Q, Chen Y, Wang B, Jiang J (2008) The TEAD/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control. Dev Cell 14: 377-387
56. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, Halder G, Lai ZC, Guan KL (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21: 2747-2761